TPG Capital Completes Buyout of Par Pharmaceutical
Date: 09/28/12
Cahill represented Bank of America Merrill Lynch as administrative agent in connection with the $1,205,000,000 credit facility, comprised of a $1,055,000,000 Term B loan and a $150,000,000 Revolving credit facility for Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. Proceeds from the facility were used in connection with the leveraged buyout of Par Pharmaceutical by TPG Capital, L.P.Cahill represented the initial purchasers in connection with the Rule 144A/Reg S offering of $490,000,000 7.375% Senior Notes due 2020 by Sky Growth Acquisition Corporation which was merged into Par Pharmaceutical.